Home207940 • KRX
add
Samsung Biologics Co Ltd
Previous close
₩796,000.00
Day range
₩792,000.00 - ₩815,000.00
Year range
₩668,000.00 - ₩880,000.00
Market cap
57.44T KRW
Avg Volume
70.08K
P/E ratio
64.15
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (KRW) | Mar 2024info | Y/Y change |
|---|---|---|
Revenue | 946.90B | 31.35% |
Operating expense | 197.05B | 32.09% |
Net income | 179.36B | 26.53% |
Net profit margin | 18.94 | -3.66% |
Earnings per share | 2.52K | 26.51% |
EBITDA | 364.72B | 24.72% |
Effective tax rate | 25.29% | — |
Balance Sheet
Total assets
Total liabilities
| (KRW) | Mar 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.06T | -30.52% |
Total assets | 16.52T | 0.86% |
Total liabilities | 6.51T | -10.23% |
Total equity | 10.01T | — |
Shares outstanding | 71.17M | — |
Price to book | 5.66 | — |
Return on assets | 3.40% | — |
Return on capital | 4.72% | — |
Cash Flow
Net change in cash
| (KRW) | Mar 2024info | Y/Y change |
|---|---|---|
Net income | 179.36B | 26.53% |
Cash from operations | 289.84B | -8.49% |
Cash from investing | 584.92B | 49.80% |
Cash from financing | -202.29B | -135.76% |
Net change in cash | 692.14B | 9.63% |
Free cash flow | 660.62B | 245.31% |
About
Samsung Biologics Co., Ltd. is a South Korean biotechnology company headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, it provides contract development and manufacturing services to the biopharmaceutical industry.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly and AstraZeneca. Samsung Biologics also partnered with Moderna for fill-finish, packaging and labeling of its mRNA vaccine, Spikevax, during the COVID-19 pandemic. Wikipedia
CEO
Founded
2011
Website
Employees
4,284
